Nov 29 2010
Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
"We are working extremely diligent to enhance our market penetration as we continue to build a high-quality therapeutics company. We have launched several new therapeutics this year and have plans to launch several more new therapeutics in 2011. In addition, we have expanded our sales coverage area by adding three new distributors," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Therefore, we believe that we have created a solid foundation to continue expanding sales, increase revenue and net income and strengthen shareholder value."
Source:
Weikang Bio-Technology Group Co., Inc.